Oriola Q2 net sales rise on Finnish wholesale business performance
Oriola Q2 net sales rise on Finnish wholesale business performance
Overview
Finland pharmaceutical distributor's Q2 net sales rose 1.7% yr/yr, adjusted EBITDA flat
Company cited higher freight costs and weaker demand for distribution services
Finnish wholesale business continued positive sales development, supporting group performance
Outlook
Oriola expects 2026 adjusted EBITDA to increase from 2025 (EUR 35.1 mln)
Company sees pharmaceutical distribution market continuing to grow in 2026
Oriola expects improved control over freight costs in coming quarters
Result Drivers
FINNISH WHOLESALE - Continued positive sales development in Finnish wholesale business supported group performance
HIGHER FREIGHT COSTS - Profitability was constrained by increased freight costs driven by higher fuel prices
WEAKER DISTRIBUTION DEMAND - Demand for pharmaceutical distribution services was somewhat weaker than anticipated
Company press release: ID:nWkr7kjF3F
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Sales |
| EUR 51.80 mln |
|
Q2 EPS |
| -EUR 0.01 |
|
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for Oriola Oyj is €1.00, about 8.6% above its July 16 closing price of €0.92
The stock recently traded at 10 times the next 12-month earnings vs. a P/E of 10 three months ago
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)